Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22203755

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2012 Feb 1
First author
Kaye SB

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2012 Feb 1;30(4):347-50. doi: 10.1200/JCO.2011.40.1489.
    note
    Source null
    related pmid
    22203759
    relationship
    Comment in

Authors and identifiers

  1. name
    Kaye SB
    type
    Author
  2. name
    Lubinski J
    type
    Author
  3. name
    Matulonis U
    type
    Author
  4. name
    Ang JE
    type
    Author
  5. name
    Gourley C
    type
    Author
  6. name
    Karlan BY
    type
    Author
  7. name
    Amnon A
    type
    Author
  8. name
    Bell-McGuinn KM
    type
    Author
  9. name
    Chen LM
    type
    Author
  10. name
    Friedlander M
    type
    Author
  11. name
    Safra T
    type
    Author
  12. name
    Vergote I
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kaye SB
    type
    Author
  2. name
    Lubinski J
    type
    Author
  3. name
    Matulonis U
    type
    Author
  4. name
    Ang JE
    type
    Author
  5. name
    Gourley C
    type
    Author
  6. name
    Karlan BY
    type
    Author
  7. name
    Amnon A
    type
    Author
  8. name
    Bell-McGuinn KM
    type
    Author
  9. name
    Chen LM
    type
    Author
  10. name
    Friedlander M
    type
    Author
  11. name
    Safra T
    type
    Author
  12. name
    Vergote I
    type
    Author
bibliography ids
  1. nci-bib-9628e1b073a6c28fb7c70683
book metadata
content sha256
402d6d9243204cc8e0ab62f5a7acbda049d34db5cfd7b5b24c4494745a9cc9b3
document type
citation
dois
  1. 10.1200/JCO.2011.36.9215
electronic publication date
display
2011 Dec 27
precision
day
year
2011
evidence scope
bibliographic_metadata_only
id
pubmed:22203755
immutable id
pubmed:22203755@402d6d9243204cc8e0ab62f5a7acbda049d34db5cfd7b5b24c4494745a9cc9b3
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
4
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
372-9
volume
30
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2012 Feb 1;30(4):347-50. doi: 10.1200/JCO.2011.40.1489.
    note
    Source null
    related pmid
    22203759
    relationship
    Comment in
outcomes validated
false
pmid
22203755
provenance
batch id
b6284687e167e7da9556
provider
NCBI PubMed ESummary
record sha256
2bba201a54ea4c8f250ec421e33b953d63621ab90935884bf9ce34cc730647ff
response sha256
64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
retrieved at
2026-09-09T23:46:45.216259+00:00
publication date
display
2012 Feb 1
precision
day
year
2012
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22203755/
title
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

Preserved source evidence · Not medical advice